Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

61. Effect of pregnancy, lactation and menopause on orthodontic tooth movement

Effect of pregnancy, lactation and menopause on orthodontic tooth movement Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

62. The prevalence of sexual dysfunction in the different menopausal stages: a systematic review

The prevalence of sexual dysfunction in the different menopausal stages: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

63. HIV and the menopause

HIV and the menopause BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 2 HIV and the menopause Introduction Over the past two decades, antiretroviral therapy (ART) has transformed HIV into a long-term condition with normal life expectancy for people stable on treatment. In 2016, 10,350 women living with HIV aged 45-56 (the age when women usually go through the menopause) attended HIV clinics in the UK. This is nearly half of all women (...) attending for HIV care in the UK, and is five times the number in 2006 1 . As the number of women living with HIV reaching their midlife grows, we are beginning to understand the importance of addressing their healthcare needs during the menopause. What is the impact of the menopause on women living with HIV? • The menopause transition can have multi-dimensional impacts on the health and well-being of women living with HIV. • There is conflicting evidence on the association between HIV and earlier age

2018 British Menopause Society

64. The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer | British Menopause Society Search for: Summary consensus statement The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer The diagnosis of the menopause and management (...) of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer 2018-12-05T16:45:20+01:00 Key points An early menopause, estrogen deficiency symptoms and arthralgia are common side effects of systemic breast cancer therapies. Symptoms may persist for the duration of treatment and in some cases continue after treatment completion. The NICE Menopause Guidance [NG23] recommends referral of women to a healthcare professional with expertise in gynaecological endocrinology for counselling about

2018 British Menopause Society

65. What can employers do to support women going through the menopause?

What can employers do to support women going through the menopause? Knowledge & Library Services (KLS) Evidence Briefing What can employers do to support women going through the menopause? Dr Caroline De Brún 19 th August 2019 What can employers do to support women going through the menopause? KLS Evidence Briefing 19 th August 2019 Research question This Evidence Briefing (EB) summarises the evidence on what employers can do to support women going through the menopause, from 1 st January 2009 (...) to 17 th July 2019. Key messages • There are around 4.3 million women in employment in the UK aged 50 years and over, most of whom will experience the menopause and its symptoms. • The limited evidence on the impact of interventions by employers to support women going through the menopause, all make similar recommendations. • Most women will go through the menopause, but the severity of their symptoms will vary. • When identifying suitable interventions, employers should remember that one size does

2018 Public Health England - Evidence Briefings

66. A review of effective herbal medicines in controlling menopausal symptoms Full Text available with Trip Pro

A review of effective herbal medicines in controlling menopausal symptoms Acute menopausal syndrome especially hot flashes, is one of the most common gynecological problems during menopause. Due to the side effects of hormone therapy, herbal and complementary medicines are always of immense interest to people in the treatment and management of the symptoms and complications of menopause.The aim of this study was to investigate the mechanisms and effects of medicinal plants employed (...) in the treatment of menopausal symptoms.This review article was carried out by examining clinical trial studies between the period of 1994 and 2016. The keywords, which include menopause, climacteric, hot flushes, flashes, herb and phytoestrogens were used to search for herbal medicines used in clinical trials for the treatment of menopausal symptoms using databases such as PubMed, Medline, Scopus, Google scholar, SID and Magiran.The results of the study showed that the medicinal plants, which include Sage

2017 Electronic physician

67. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. (Abstract)

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis.In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate (...) in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10).Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.Lilly.Copyright © 2018 Elsevier Ltd. All rights reserved.

2017 Lancet Controlled trial quality: predicted high

68. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. Full Text available with Trip Pro

Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. Health outcomes from the Women's Health Initiative Estrogen Plus Progestin and Estrogen-Alone Trials have been reported, but previous publications have generally not focused on all-cause and cause-specific mortality.To examine total and cause-specific cumulative mortality, including during the intervention and extended postintervention follow-up, of the 2 Women's

2017 JAMA Controlled trial quality: predicted high

69. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study Full Text available with Trip Pro

Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study Double-blind randomized studies on the effects of oral postmenopausal hormone therapies were stopped mainly because of increased risk of stroke. We aimed to assess the risk of all strokes and various subtypes associated with hormone therapy and explore the influence of regimens and routes of administration.A national historical cohort of women aged 51 to 70 years from 1995 to 2010 was established

2017 EvidenceUpdates

70. Equine oestrogens + bazedoxifene (Duavive) and menopause. Inadequately evaluated harms

Equine oestrogens + bazedoxifene (Duavive) and menopause. Inadequately evaluated harms Prescrire IN ENGLISH - Spotlight ''Equine oestrogens + bazedoxifene (Duavive°) and menopause. Inadequately evaluated harms'', 1 July 2017 {1} {1} {1} | | > > > Equine oestrogens + bazedoxifene (Duavive°) and menopause. Inadequately evaluated harms Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight Equine oestrogens + bazedoxifene (Duavive°) and menopause. Inadequately evaluated harms FEATURED REVIEW A new product combining equine oestrogens and bazedoxifene (Duavive°, Pfizer) has been authorised in the European Union for menopausal disorders in non-hysterectomised postmenopausal women. Past experience suggests that this new combination should be considered with caution, and avoided until these foreseeable adverse effects have been properly evaluated. Full

2017 Prescrire

71. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Full Text available with Trip Pro

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Hot flushes affect 70% of menopausal women and often severely impact physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but is not without risk. Neurokinin B signalling is increased in menopausal women, and has been implicated as an important mediator of hot flushes.This phase 2, randomised, double-blind (...) , placebo-controlled, single-centre, crossover trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal hot flushes. Eligible participants were healthy women aged 40-62 years, having seven or more hot flushes in every 24 h of which some were reported as being severe or bothersome, who had not had a menstrual period for at least 12 months, and who had not been taking any medication shown to improve menopausal flushes in the preceding 8 weeks. Participants

2017 Lancet Controlled trial quality: predicted high

72. The Relationship between Physical Activity and General Health among Menopausal Women in Ahvaz, Iran Full Text available with Trip Pro

The Relationship between Physical Activity and General Health among Menopausal Women in Ahvaz, Iran Most women experience significant changes in their general health status during menopause, which negatively affects their quality of life. Physical activity has also been shown to enhance quality of life. However, little is known about the effect of physical activity on women's health during the menopausal transition. This study aimed to determine the relationship between physical activity (...) and general health among menopausal women in Ahvaz, Iran.This cross sectional study was carried out on 600 menopausal women using cluster random sampling during 2013-2014. Data collection tools were three questionnaires; women's demographic characteristics, the Goldenberg's questionnaire, and International physical activity questionnaire (IPAQ). Data were analyzed using descriptive and inferential statistics through SPSS version 19. The statistical tests were performed at the 95% confidence interval.There

2017 Electronic physician

73. Examining Psychometric Characteristics of a Menopausal Health Questionnaire: Translation and Psychometric Evaluation of the Persian Version Full Text available with Trip Pro

Examining Psychometric Characteristics of a Menopausal Health Questionnaire: Translation and Psychometric Evaluation of the Persian Version Menopause is a natural event in a woman's life which affects her general health and quality of life. However, currently there is no Persian instrument for measuring health status during this period. Therefore, the present study was performed to assess the validity and reliability of the Persian version of the Menopausal Health Questionnaire in Iran.The (...) correlation coefficient (ICC) was assessed to be 0.93.The 14-item Menopausal Health Questionnaire is a valid and reliable instrument to assess postmenopausal women's health.

2017 Electronic physician

74. The 2017 hormone therapy position statement of The North American Menopause Society

The 2017 hormone therapy position statement of The North American Menopause Society Copyright @ 2017 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. POSITION STATEMENT The 2017 hormone therapy position statement of The North American Menopause Society Abstract The2017HormoneTherapyPositionStatementofTheNorthAmericanMenopauseSociety(NAMS)updatesthe 2012HormoneTherapyPositionStatementofTheNorthAmericanMenopauseSocietyandidentifiesfutureresearch needs (...) . An Advisory Panel of clinicians and researchers expert in the field of women’s health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensusonrecommendations,usingthelevelofevidencetoidentifythestrengthofrecommendationsandthequality of the evidence. The Panel’s recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS

2017 The North American Menopause Society

75. Herbal medicine (danggui liuhuang decoction) for treating menopausal symptoms: a systematic review of randomized clinical trials

Herbal medicine (danggui liuhuang decoction) for treating menopausal symptoms: a systematic review of randomized clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

76. The association between chronic diseases and age at the onset of menopause: a systematic review protocol

The association between chronic diseases and age at the onset of menopause: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

77. Management of menopausal symptoms in women with a history of breast cancer

Management of menopausal symptoms in women with a history of breast cancer Management of menopausal symptoms in women with a history of breast cancer Management of menopausal symptoms in women with a history of breast cancer December 2016 | Incorporates published evidence to November 2015 This guideline includes Evidence Summaries and Recommendations based on available evidence about the effectiveness and safety of different therapies for managing menopausal symptoms in women after breast (...) cancer. The guideline provides health professionals and breast cancer patients with information to support decisions regarding the choice of particular therapies for the management of menopausal symptoms in the context of past or ongoing treatment for breast cancer. © Cancer Australia 2016 Management of menopausal symptoms in women with a history of breast cancer page 1 of 181Table of contents Management of menopausal symptoms in women with a history of breast cancer 1 Background 5 Grading

2017 Cancer Australia